Lantern Pharma Inc
$ 2.54
4.96%
16 Apr - close price
- Market Cap 27,236,400 USD
- Current Price $ 2.54
- High / Low $ 2.82 / 2.43
- Stock P/E N/A
- Book Value 0.58
- EPS -1.63
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.61 %
- ROE -1.24 %
- 52 Week High 5.74
- 52 Week Low 1.11
About
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
Analyst Target Price
$20.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2025-12-31 | 2025-11-05 | 2025-08-13 | 2025-05-07 | 2025-03-17 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-18 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.362 | -0.36 | -0.39 | -0.4 | -0.42 | -0.54 | -0.42 | -0.46 | -0.51 | -0.39 | -0.29 | -0.44 |
| Estimated EPS | None | -0.46 | -0.44 | -0.53 | -0.43 | -0.51 | -0.56 | -0.55 | -0.43 | -0.4 | -0.45 | -0.43 |
| Surprise | 0 | 0.1 | 0.05 | 0.13 | 0.01 | -0.03 | 0.14 | 0.09 | -0.08 | 0.01 | 0.16 | -0.01 |
| Surprise Percentage | None% | 21.7391% | 11.3636% | 24.5283% | 2.3256% | -5.8824% | 25% | 16.3636% | -18.6047% | 2.5% | 35.5556% | -2.3256% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LTRN
2026-04-14 15:09:53
Lantern Pharma Inc. has launched withZeta.ai, the world's first multi-agentic AI co-scientist designed for rare cancer drug discovery and development. The platform, available through various subscription tiers, aims to accelerate research, reduce costs, and increase precision in finding therapies for rare cancers. Debut events are scheduled for April 16, 2026, at Nasdaq MarketSite and from April 17-22, 2026, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
2026-04-14 12:40:13
Lantern Pharma Inc. has launched withZeta.ai, a multi-agentic AI co-scientist platform for rare cancer drug discovery and development, now available for subscription. This new platform aims to accelerate research, reduce costs, and provide a non-dilutive revenue stream for Lantern Pharma. The launch includes debut events at Nasdaq MarketSite on April 16, 2026, and public demonstrations at AACR 2026 in San Diego from April 17-22, inviting investors and researchers to experience its capabilities.
2026-04-14 12:40:13
Lantern Pharma Inc. (NASDAQ:LTRN) has launched its withZeta.ai platform, now commercially available for rare cancer drug discovery and biomedical research with a subscription model. The company's stock surged 26% following the announcement, and they plan to demonstrate the platform at investor briefings and the American Association for Cancer Research Annual Meeting. Despite being unprofitable with projected losses for fiscal 2026, Lantern Pharma improved its net loss in Q4 2025.
2026-04-14 12:09:53
Lantern Pharma Inc. has launched withZeta.ai, described as the world's first multi-agentic AI co-scientist for rare cancer drug discovery and development. The platform is now commercially live, offering subscriptions to generate a new, non-dilutive revenue stream for shareholders. Its debut will be highlighted at a private investor briefing at Nasdaq MarketSite and public demonstrations at the American Association for Cancer Research Annual Meeting.
2026-04-10 12:10:08
Lantern Pharma (NASDAQ: LTRN) recently furnished an investor presentation and conducted a live demonstration of its withZeta.ai platform, an AI co-scientist for rare cancer drug discovery and development. The presentation detailed the platform's capabilities, commercial architecture, market opportunity, and revenue strategy. Lantern Pharma emphasized that withZeta.ai aims to leverage AI, machine learning, and genomic data to streamline oncology drug discovery and identify patient populations for targeted therapies.
2026-04-10 12:10:08
Lantern Pharma (LTRN) recently hosted a live demonstration of its withZeta.ai platform, an AI co-scientist designed for rare cancer drug discovery and trial design. The company outlined the platform's capabilities, its commercial architecture, and a near-term revenue strategy focusing on software licensing and subscriptions in the rare cancer market. A replay of the demonstration and presentation is available via a provided link as Exhibit 99.1 from its SEC filing.
